Salonpas Launches SalonpasPro.com

 SalonpasPro.com is newly released for healthcare professionals and includes information on all Salonpas products as well as clinical studies and key opinion leader commentary. The new website also offers Samples and product support materials to healthcare professionals who register.

Salonpas offers a full line of patches, cream, roll-on, gel, and spray products that employ a variety of active ingredients, formulas, and technologies. Salonpas Patches include:

• Salonpas Pain Relief Patch LARGE - The first FDA-approved OTC topical pain reliever that provides powerful relief for up to 12 hours and the only OTC patch indicated to treat mild and moderate pain.
• Salonpas Pain Relieving Patch - Clinically proven to reduce pain severity and improve brief pain inventory (BPI) quality of life measures.
• Salonpas Lidocaine Pain-Relieving Gel-Patch - The #1 selling OTC patch in the United States, which provides the maximum strength lidocaine without a prescription.

The Salonpas portfolio broadly provides temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, sprains, bruises and strains.

Product Samples, Clinical Studies, and Guidelines information

SalonpasPro.com offers samples, clinical studies, and guidelines information, all beneficial to medical professionals.

"Providing healthcare professionals with clinical evidence, product information and product samples, supports their treatment recommendation to patients who are suffering from pain. HCP recommendations ensure people in pain have access to safe and effective topical OTC analgesics," said John Incledon, President, Hisamitsu America, the marketers of Salonpas®, the world's number one OTC pain patch brand.

The trend of increasing recommendations for topical pain relievers follows an expanding set of guidance and recommendations from leading medical authorities. In guidance issued in August 2020, the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) recommend the use of topical non-steroidal anti-inflammatory drugs (NSAIDS) as first-line therapy for treating acute, non-low back pain from musculoskeletal injuries in outpatient settings. Earlier, the Centers for Disease Control (CDC) issued guidance to clinicians to consider topical pain relievers as first-line therapy in response to the Opioid crisis.

Clinical Study Support and Expert Opinions

SalonpasPro.com also contains a number of clinical studies including a recent pain management study, titled, 'Personalized Pain Therapy: Artificial Intelligence (AI) Utilized to Predict Patient Response to OTC Topical Analgesics." It is based on data from the previously published RELIEF study which studied Salonpas Pain Relieving Patch and found that patients treated with Salonpas reported greater reductions in pain severity, better quality of life outcomes, and less usage of oral pain medicines than those patients who were not treated with Salonpas. This study is published in Anesthesia & Research, an international, peer-reviewed scientific journal. Healthcare professionals can access this study here.

Also, reprints of the Higashi study, which led to the first FDA approval for an OTC topical pain reliever can also be requested.

Medical professionals visiting the site can access a Q&A with Dr. Jeffrey Gudin, an esteemed pain management physician and Salonpas advisor who shares his insights.

"For over 80 years, Salonpas has delivered on our mission to improve people's quality of life through topical pain relief products," says Incledon. "Our family of patches, cream, roll-on, gel, and spray are efficacious, readily available over-the-counter, safe and non-addictive. We call that ‘Good Medicine.'"